Prognostication of survival using cardiac troponins and N-terminal pro-brain natriuretic peptide in patients with primary systemic amyloidosis undergoing peripheral blood stem cell transplantation

Blood

Volumn 104, Issue 6, 2004, Pages 1881-1887

  Dispenzieri, Angela ^a   Gertz, Morie A ^b   Kyle, Robert A ^b   Lacy, Martha Q ^b   Burritt, Mary F ^b   Therneau, Terry M ^b   McConnell, Joseph P ^b   Litzow, Mark R ^b   Gastineau, Dennis A ^b   Tefferi, Ayalew ^b   Inwards, David J ^b   Micallef, Ivana N ^b   Ansell, Stephen M ^b   Porrata, Luis F ^b   Elliott, Michelle A ^b   Hogan, William J ^b   Rajkumar, S Vincent ^b   Fonseca, Rafael ^b   Greipp, Philip R ^b   Witzig, Thomas E ^b   Lust, John A ^b   Zeldenrust, Steven R ^b   Snow, Denise S ^b   Hayman, Susan R ^b   McGregor, Christopher G A ^b   Jaffe, Allan S ^b   more..

^a MAYO CLINIC   (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

BIOLOGICAL MARKER; BRAIN NATRIURETIC PEPTIDE; N TERMINAL PRO BRAIN NATRIURETIC PAPTIDE; TROPONIN; TROPONIN I; TROPONIN T; UNCLASSIFIED DRUG;

ADULT; AGED; AMYLOIDOSIS; ARTICLE; CELL SELECTION; CONTROLLED STUDY; FEMALE; FOLLOW UP; HUMAN; HUMAN CELL; MAJOR CLINICAL STUDY; MALE; PERIPHERAL BLOOD STEM CELL TRANSPLANTATION; PILOT STUDY; PLASMA CELL DYSCRASIA; PRIORITY JOURNAL; PROGNOSIS; RISK ASSESSMENT; SURVIVAL;

EID: 4444268210     PISSN: 00064971     EISSN: None     Source Type: Journal    
DOI: 10.1182/blood-2004-01-0390     Document Type: Article

References (40)

1. Kyle RA, Greipp PR. Amyloidosis (AL): clinical and laboratory features in 229 cases. Mayo Clinic Proc. 1983;58:665-683.
2. Kyle RA, Gertz MA. Primary systemic amyloidosis: clinical and laboratory features in 474 cases. Semin Hematol. 1995;32:45-59.
3. Kyle RA, Gertz MA, Greipp PR, et al. A trial of three regimens for primary amyloidosis: colchicine alone, melphalan and prednisone, and melphalan, prednisone, and colchicine [see comments]. New Engl J Med. 1997;336:1202-1207.
4. Skinner M, Anderson J, Simms R, et al. Treatment of 100 patients with primary amyloidosis: a randomized trial of melphalan, prednisone, and colchicine versus colchicine only. Am J Med. 1996;100:290-298.
5. Comenzo RL, Gertz MA. Autologous stem cell transplantation for primary systemic amyloidosis. Blood. 2002;99:4276-4282.
6. Gertz MA, Lacy MQ, Dispenzieri A, et al. Stem cell transplantation for the management of primary systemic amyloidosis. Am J Med. 2002;113:549-555.
7. Dember LM, Sanchorawala V, Seldin DC, et al. Effect of dose-intensive intravenous melphalan and autologous blood stem-cell transplantation on al amyloidosis-associated renal disease. Ann Intern Med. 2001;134:746-753.
8. Moreau P, Leblond V, Bourquelot P, et al. Prognostic factors for survival and response after high-dose therapy and autologous stem cell transplantation in systemic AL amyloidosis: a report on 21 patients. Br J Haematol. 1998;101:766-769.
9. Dispenzieri A, Lacy M, Kyle RA, et al. Eligibility for hematopoietic stem-cell transplantation for primary systemic amyloidosis is a favorable prognostic factor for survival. J Clin Oncol. 2001;19:3350-3356.
10. Dispenzieri A, Kyle RA, Gertz MA, et al. Survival in patients with primary systemic amyloidosis and raised serum cardiac troponins. Lancet. 2003;361:1787-1789.
11. Jaffe AS, Ravkilde J, Roberts R, et al. It's time for a change to a troponin standard. Circulation. 2000;102:1216-1220.
12. Ottani F, Galvani M, Nicolini FA, et al. Elevated cardiac troponin levels predict the risk of adverse outcome in patients with acute coronary syndromes. Am Heart J. 2000;140:917-927.
13. Missov E, Mair J. A novel biochemical approach to congestive heart failure: cardiac troponin T. Am Heart J. 1999;138:95-99.
14. Wu AH, Smith A, Wieczorek S, et al. Biological variation for N-terminal pro- and B-type natriuretic peptides and implications for therapeutic monitoring of patients with congestive heart failure. Am J Cardiol. 2003;92:628-631.
15. James SK, Lindahl B, Siegbahn A, et al. N-terminal pro-brain natriuretic peptide and other risk markers for the separate prediction of mortality and subsequent myocardial infarction in patients with unstable coronary artery disease: a Global Utilization of Strategies To Open occluded arteries (GUSTO)-IV substudy. Circulation. 2003;108:275-281.
16. Palladini G, Campana C, Klersy C, et al. Serum N-terminal pro-brain natriuretic peptide is a sensitive marker of myocardial dysfunction in AL amyloidosis. Circulation. 2003;107:2440-2445.
17. Dispenzieri A, Gertz MA, Kyle RA, et al. Serum cardiac troponins and N-terminal pro-brain natriuretic peptide: a staging system for primary systemic amyloidosis. J Clin Oncol. In press.
18. Miller WL, Wright RS, McGregor CG, et al. Troponin levels in patients with amyloid cardiomyopathy undergoing cardiac transplantation. Am J Cardiol. 2001;88:813-815.
19. Apple FS, Wu AH, Jaffe AS. European Society of Cardiology and American College of Cardiology guidelines for redefinition of myocardial infarction: how to use existing assays clinically and for clinical trials. Am Heart J. 2003;144:981-986.
20. Hollander M, Wolfe DA. Nonparametric Statistical Methods. New York, NY: John Wiley and Sons, Inc; 1973.
21. Mehta CR, Patel NR. A network algorithm for the exact treatment of Fisher's exact test in RxC contingency tables. J Am Stat Assoc. 1983;78:427-434.
22. Kaplan EL, Meier P. Nonparametric estimation from incomplete observations. J Am Stat Assoc. 1958;53:457-481.
23. Peto R, Peto J. Asymptotically efficient rank invariant procedures (with discussion). J Royal Stat Soc, Series A. 1972;135:185-207.
24. Cox DR. Regression models and life-tables (with discussion). J Royal Stat Soc, Series B. 1972;34:187-220.
25. Morrow DA, Braunwald E. Future of biomarkers in acute coronary syndromes: moving toward a multimarker strategy. Circulation. 2003;108:250-252.
26. Cueto-Garcia L, Reeder GS, Kyle RA, et al. Echocardiographic findings in systemic amyloidosis: spectrum of cardiac involvement and relation to survival. J Am Coll Cardiol. 1985;6:737-743.
27. Gertz MA, Kyle RA, Greipp PR. The plasma cell labeling index: a valuable tool in primary systemic amyloidosis. Blood. 1989;74:1108-1111.
28. Gertz MA, Kyle RA. Prognostic value of urinary protein in primary systemic amyloidosis (AL). Am J Clin Pathol. 1990;94:313-317.
29. Gertz MA, Kyle RA. Amyloidosis: prognosis and treatment. Sem Arthritis Rheum. 1994;24:124-138.
30. Klein AL, Hatle LK, Taliercio CP, et al. Prognostic significance of Doppler measures of diastolic function in cardiac amyloidosis: a Doppler echocardiography study. Circulation. 1991;83:808-816.
31. Kyle RA, Greipp PR, O'Fallon WM. Primary systemic amyloidosis: multivariate analysis for prognostic factors in 168 cases. Blood. 1986;68:220-224.
32. Patel AR, Dubrey SW, Mendes LA, et al. Right ventricular dilation in primary amyloidosis: an independent predictor of survival. Am J Cardiol. 1997;80:486-492.
33. Perfetti V, Colli Vignarelli M, Anesi E, et at. The degrees of plasma cell clonality and marrow infiltration adversely influence the prognosis of AL amyloidosis patients. Haematologica. 1999;84:218-221.
34. Comenzo RL, Sanchorawala V, Fisher C, et al. Intermediate-dose intravenous melphalan and blood stem cells mobilized with sequential GM+G-CSF or G-CSF alone to treat AL (amyloid light chain) amyloidosis. Br J Haematol. 1999;104:553-559.
35. Sanchorawala V, Wright DG, Seidin DC, et al. An overview of the use of high-dose melphalan with autologous stem cell transplantation for the treatment of AL amyloidosis. Bone Marrow Transplant. 2001;28:637-642.
36. Roberts MA, Fernando D, Macmillan N, et al. Single and serial measurements of cardiac troponin I in asymptomatic patients on chronic hemodialysis. Clin Nephrol. 2004;61:40-46.
37. Ishii J, Nomura M, Okuma T, et al. Risk stratification using serum concentrations of cardiac troponin T in patients with end-stage renal disease on chronic maintenance dialysis. Clin Chim Acta. 2001;312:69-79.
38. Iliou MC, Fumeron C, Benoit MO, et al. Prognostic value of cardiac markers in ESRD: Chronic Hemodialysis and New Cardiac Markers Evaluation (CHANCE) study. Am J Kidney Dis. 2003;42:513-523.
39. Apple FS, Murakami MM, Pearce LA, Herzog CA. Predictive value of cardiac troponin I and T for subsequent death in end-stage renal disease. Circulation. 2002;106:2941-2945.
40. Cueto-Garcia L, Tajik AJ, Kyle RA, et al. Serial echocardiographic observations in patients with primary systemic amyloidosis: an introduction to the concept of early (asymptomatic) amyloid infiltration of the heart. Mayo Clin Proc. 1984;59:589-597.